Safety, tolerability and immunogenicity of a condensed, multi-dose prime regimen of PfSPZ Vaccine for the prevention of Plasmodium falciparum malaria infection

Abstract Background The World Health Organization (WHO) has called for new malaria vaccines with > 90% efficacy against Plasmodium falciparum infection to expand the anti-disease benefit provided by the RTS,S/AS01 and R21/Matrix M subunit vaccines currently administered to infants and young children...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Andrea A. Berry, Thomas L. Richie, L. W. Preston Church, Matthew B. Laurens, Colleen Boyce, Natasha KC, Sudhaunshu Joshi, Abra Rachida Koudjra, Lauryn Butler, Mei-Chun Chen, Yonas Abebe, Tooba Murshedkar, Eric R. James, Peter F. Billingsley, B. Kim Lee Sim, Stephen L. Hoffman, Kirsten E. Lyke
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	BMC 2025-03-01
Serie:	Malaria Journal
Soggetti:	PfSPZ Vaccines Plasmodium falciparum Malaria Safety Immunogenicity
Accesso online:	https://doi.org/10.1186/s12936-025-05299-5
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!